Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate adverse events reported by subjects. After: Measure: Phase 1/2: Incidence and severity of adverse events (AEs) Measure: Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids Measure: Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids.
Planned enrollment increased by 50 participants
Before: 24 participants (planned). After: 74 participants (planned).
Phase changed
Before: PHASE1, PHASE2. After: PHASE2, PHASE3.